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Abstract 
Aims: To report the outcomes of a cohort of patients with renal cell carcinoma (RCC) treated 
using stereotactic ablative body radiotherapy (SABR). 
Materials and methods: Patients treated with SABR for primary RCC from 1 January 2012 to 
1 April 2015 were retrospectively reviewed. Patients were non-surgical candidates treated 
with doses ranging from 30 Gy to 40 Gy in 5 fractions. The tumour sizes and serum 
creatinine were compared between the pre-treatment assessment and subsequent follow-
up assessments. The worst acute and late grade ≥2 toxicity rates were recorded. 
Results: 16 patients were included in this study. The median follow-up was 19 months (range 
7 – 30). 11 patients had stable disease, 4 had partial responses, and none had progressive 
disease, indicating a local control rate of 100%. One patient had grade 2 acute nausea, and 
two patients had grade 4 renal toxicities (two patients with pre-existing stage 4-5 chronic 
kidney disease required dialysis following SABR). Four out of four patients with pre-SABR 
symptoms (pain and / or haematuria) had symptomatic relief following SABR. 
Conclusion: SABR for RCC is safe, the toxicities are minimal, and the local control is excellent 
at early follow-up. This technique should be further evaluated in prospective clinical trials. 
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Kidney cancers, primarily renal cell carcinomas (RCCs) are the tenth most common 
malignancy in Canada, with 6200 estimated new cases in 2015 [1]. The greatest numbers 
occur in the 60 – 69 year old age group, however a significant number of patients are 
diagnosed at an older age [2]. 
The standard treatment of RCC in those with localised disease is surgery, which is curative in 
the majority of patients. However, elderly patients and those with significant comorbidity 
may not be surgical candidates. These patients are usually considered for active 
surveillance [3]. Large series have demonstrated the safety of active surveillance in the 
management of small renal masses (SRMs), showing that the majority of SRMs grow slowly, 
and have low rates of metastasis [3]. However, a pooled analysis demonstrated certain risk 
factors being associated with a higher risk of progression to metastasis while on active 
surveillance, including increased age, greater initial tumour dimension, and higher growth 
rate [3]. Additionally, SRMs represent a heterogeneous entity, with up to 20% being benign 
masses, which undoubtedly contributes to the low rates of progression noted in the active 
surveillance studies [3]. 
Patients with progressing or symptomatic tumours who are not surgical candidates are often 
considered for local ablative therapies. These approaches include radiofrequency ablation, 
cryoablation, and stereotactic ablative body radiotherapy (SABR). Radiofrequency ablation 
and cryoablation are limited by low control rates with tumours larger than 3-4 cm, the fact 
that there is a high risk of complications in treating tumours in the hilum or central collecting 
system, and that both are still invasive procedures that require either percutaneous or 
laparoscopic access to the tumour [4,5]. 
SABR offers a completely non-invasive approach that may potentially overcome many of the 
limitations of the other local ablative therapies. SABR refers to the precise delivery of highly 
conformal and image-guided hypofractionated external beam radiotherapy, delivered in few 
fractions with doses at least biologically equivalent to conventional radical courses of 
radiotherapy [6]. SABR allows highly conformal dose distributions with high doses delivered 
to the target, and steep dose gradients beyond the target such that doses to surrounding 
organs at risk (OARs) are minimized [6]. Previous studies of conventionally fractionated 
radiotherapy in RCC have demonstrated that RCC is relatively radioresistant [7]. However, 
subsequent studies of SABR delivered to RCC metastases have shown excellent rates of local 
control, indicating that SABR can potentially overcome this resistance [7]. 
SABR in primary RCC is still a new field, with limited published experience at this stage [8]. 
We have reported on the outcomes achieved in an initial cohort of patients treated with 
SABR for RCC in non-surgical candidates. 
Materials and Methods 
Patients 
This was a retrospective review of patients with RCC treated with SABR to the primary 
tumour from 1 January 2012 to 1 April 2015, with at least 6 months of follow-up data. This 
study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board. 
Patients who received prior surgery or ablative therapy to the primary site but had 
recurred/progressed at the primary site, and patients with regional nodal and/or distant 
metastatic disease were also included in this analysis, as long as the primary tumour was 
treated with SABR. 
A diagnosis of RCC was made either by biopsy or radiological appearances (where biopsy 
was not possible). All patients were first assessed by a urologist and deemed not to be 
surgical candidates before being considered for SABR. 
At baseline, all patients were assessed with CT scans of the abdomen and pelvis, and blood 
tests including serum creatinine. Other investigations including MRI scans of the abdomen 
and nuclear medicine scans for differential renal function and glomerular filtration rate 
(GFR) were ordered at the treating physician’s discretion in some of the patients. 
Patients with poor baseline renal function were cautioned about the risk of requiring dialysis 
after having SABR. 
Radiotherapy technique 
The patients were immobilized using the BodyFIX (Elekta AB, Stockholm, Sweden) dual 
vacuum immobilization device. Four-dimensional CTs were acquired with phase-binning 
algorithms for image reconstruction. The treating radiation oncologist delineated the gross 
tumour volume (GTV) on the 0% (peak inspiratory) and 50% (peak expiratory) image sets. 
These volumes were combined by Boolean addition to generate the internal target volume 
(ITV), and then expanded by 5 mm to generate the planning target volume (PTV). The 
average image dataset was used for radiotherapy dose calculation. 
Radiotherapy planning was performed on the Pinnacle 3 (Phillips Medical Systems, Madison, 
WI) treatment planning system. Earlier patients were treated using step-and-shoot intensity-
modulated radiotherapy (IMRT), whereas recent patients were treated using volumetric-
modulated arc therapy (VMAT). The prescription dose was 40 Gy in 5 fractions. However, 
the prescription dose was lowered as required to meet OAR constraints, to a minimum 
prescription dose of 30 Gy in 5 fractions. The target coverage objectives were ITV V100% ≥ 
99%, PTV V95% ≥ 99%, and PTV V110% < 1%. The dose constraints for the organs at risk 
(OARs) are listed in Table 1. The majority of these dose constraints were derived from the 
American Association of Physicists in Medicine Task Group 101 (AAPM TG 101) report [9]. A 
typical dose distribution is demonstrated in Fig 1. 
Treatment was delivered on alternate days using an Elekta Synergy (Elekta AB) linear 
accelerator equipped with the Elekta Synergy Beam Modulator (high resolution 4 mm 
multileaf collimator), a kilovoltage cone beam CT (CBCT) image-guidance system, and the 
Hexapod (Elekta AB) robotic couch permitting 6 degrees of freedom patient positioning. 
Prior to the delivery of each fraction, patients were imaged using CBCT, and by comparing 
these images with the planning CT scan, patient positioning was corrected in 6 degrees of 
freedom using the Hexapod robotic couch. After the patient positioning was adjusted, a 
verification CBCT was acquired to confirm position as required. If accurate patient 
positioning was confirmed, the treatment was initiated, or else the above procedures were 
repeated. 
Follow-up 
Patients were followed up every 3 to 4 months for the first 2 years. After that, follow-up was 
decreased to every 6 months. Prior to each follow-up appointment, patients had CT scans of 
the abdomen and pelvis, and blood tests including serum creatinine. 
Outcomes 
Primary tumour response was assessed using Response Evaluation Criteria In Solid Tumours 
(RECIST) criteria [10]. Local control was defined as complete response, partial response, or 
stable disease. The worst acute and late toxicities grade 2 or greater were recorded for each 
patient according to Common Terminology Criteria for Adverse events version 4.0 [11]. The 
serum creatinine was recorded at each follow-up visit, and then used to estimate the GFR 
using the Modified Diet in Renal Diseases formula [12]. Each patient was then classified by 
chronic kidney disease (CKD) stage as per the Kidney Disease Outcomes Quality Initiative 
(KDOQI) guidelines [13]. The number of patients who had troubling symptoms attributable 
to the primary RCC at baseline and at follow-up was recorded. 
Results 
A total of 16 patients were included in this study. The median follow-up was 19 months 
(range 7 – 30 months). The patient baseline characteristics are listed in Table 2. Four 
patients (25%) received the top dose of 40 Gy; nine patients (63%) received 35 Gy; one 
patient (6%) received 32.5 Gy; and one patient (6%) received 30 Gy. Three patients were 
treated with step-and-shoot IMRT, and the remainder were treated with VMAT. 
Dose/volume metrics for OARs are listed in Table 3. 
Eleven patients had stable disease, and five had partial responses. No patient had either 
complete response or progressive disease. This translated to a local control rate of 100% as 
previously defined. Six out of 14 patients (43%) with evaluable scans at 3 months post SABR 
had a transient increase in tumour size, followed by reduction in tumour size on the 
subsequent scan. The overall change in tumour size between the pre-radiotherapy scan and 
the final follow-up scan was a decrease by 12.5% (standard deviation 23.7%). The spider plot 
in Fig 2 demonstrates the changes in tumour sizes over the length of follow-up. An example 
case showing partial response on serial imaging is demonstrated in Fig 3. 
Eleven patients (69%) had overall deteriorations in eGFR by the end of the study period, 
however only one patient changed CKD stages between baseline and last follow-up (dialysis 
was initiated, increasing the patients’ CKD stage from 4 to 5). The mean change in eGFR over 
the entire length of follow-up was a decline of 14.4%. The spider plot in Fig 4 demonstrates 
the changes in eGFR over the length of follow-up, with the most extreme deteriorations 
noted in the patients with baseline stage 4-5 CKD. 
Two patients with pre-existing stage 4-5 CKD had deteriorations in their kidney function 
following SABR such that they later required dialysis. These patients are technically classified 
as having grade 4 toxicities. Both patients were counselled on the high likelihood of 
requiring dialysis after SABR. One was a 73-year-old lady with a left sided renal mass 
discovered incidentally on imaging, with a baseline creatinine of 296 μmol/L (eGFR 13 
ml/min, stage 5 CKD). She was determined not to be a surgical candidate at the time the 
mass was discovered, and therefore observed for 2 years. At that stage, the mass had grown 
to 4.5 cm, and she was therefore referred for arterial embolisation followed by 
percutaneous RFA. The RFA was attempted twice and aborted both times due to patient 
discomfort. The mass had grown to 5.3 cm by the time she was referred for SABR. The other 
patient was a 76-year-old lady with diabetic nephropathy with a baseline creatinine of 236 
μmol/L (eGFR 17ml/min, stage 4 CKD), and a biopsy-proven clear cell carcinoma of the left 
kidney. Her urologist’s opinion was that a nephrectomy would result in an immediate 
requirement for dialysis, and was therefore referred for SABR. She did not have any other 
interventions prior to SABR. 
Other patients with deteriorations in renal function were not classified as having toxicities 
because they did not change CKD stages compared to their baseline stage. One patient 
developed acute grade 2 nausea and vomiting following SABR, however this resolved with 
antiemetics. There were no other recorded grade ≥ 2 toxicities. 
Four patients (27%) were symptomatic with flank pain and/or hematuria prior to SABR. All of 
these patients’ symptoms resolved after SABR. Of the ten patients who had localized disease 
at the time of SABR, none developed regional or distant metastases at the time of the last 
follow-up. Two patients died following SABR, both of whom had metastatic disease at the 
time of SABR. One patient died at 15 months and the other at 23 months after SABR. 
Discussion 
We have described the successful delivery of SABR in an initial cohort of 16 patients with 
RCC who were not surgical candidates. SABR for primary RCC is a new and evolving 
technique, and as such, our study is among the first to describe early outcomes [8]. 
At early follow-up, we have demonstrated an excellent local control rate of 100%. This result 
is consistent with previous publications. Ponsky et al. performed a Phase I dose-escalation 
study on 19 patients with RCC [14]. They treated groups of 3-6 patients at increasing dose 
levels ranging from 24 Gy to 48 Gy in 4 fractions. Their median follow-up was 13.7 months. 
By examining the imaging using RECIST criteria, they also had a local control rate of 100%. 
Post-SABR biopsies were performed on 11 of these patients (at a median of 9 months post-
SABR), 7 of which were positive. One of the initially positive patients had a second biopsy, 
which turned negative without further therapy. The significance of these biopsy results is 
questionable. There currently is no data to guide how to interpret these biopsies in the 
setting of RCC, post SABR. Multiple studies of post-radiation biopsies in various other 
malignancies including prostate and head and neck cancer have demonstrated that initially 
positive biopsies may become negative on subsequent biopsies (possibly due to the cell-
cycle-specific nature of radiation injury) [15,16]. As a result of this, it has been proposed that 
post-radiation prostate biopsies not be performed within 18 months of radiotherapy [15]. 
Furthermore, radiation atypia in benign tissue may make the interpretation of biopsies 
difficult [15]. In prostate cancer, post-radiotherapy biopsies done after an appropriate delay 
have been shown to have some prognostic significance, however are still not accurate 
enough for predicting outcomes [15]. As such, it is uncertain whether all of these patients 
with positive biopsies would fail without further therapy. It would be interesting to correlate 
these patients with positive biopsies with clinical outcomes on long-term follow-up. 
McBride et al. performed a Phase I dose escalation study on 15 patients with RCC [17]. They 
treated patients at increasing dose levels ranging from 21 Gy to 48 Gy in 3 fractions. The 
median follow-up was 36.7 months. They reported two local failures at 30.7 months and 
31.2 months, both in patients in the low dose cohorts (21 Gy and 27 Gy). 
Siva et al. performed a systematic review of 10 publications (including 126 patients) of SABR 
for primary RCC [8]. The weighted local control reported was 94%. 
We have demonstrated low toxicity rates with one grade 2 acute toxicity and two grade 4 
late toxicities (both cases of which were expected renal toxicities in patients with underlying 
CKD). This result is also consistent with previous publications. Ponsky et al.’s study  
(described above) reported one grade 4 acute duodenal ulcer, two grade 3 renal toxicities, 
one grade 2 urinary incontinence, and one late grade 4 duodenal ulcer [14]. McBride et al.’s 
study (described above) had one patient with grade 3 renal dysfunction [17]. Siva et al.’s 
systematic review (described above) reported 3.8% grade 3 or higher toxicities [8]. 
We also demonstrated deteriorations in renal function in 11 patients, with the overall 
change in renal function in the whole cohort over the whole duration of follow-up being a 
decline of 14.4%. At the current follow-up, this is less than the 33% decline noted in McBride 
et al.’s study [17], however these numbers may deteriorate further with time. 
Interestingly, we demonstrated that all four patients with symptoms including pain and/or 
haematuria prior to SABR experienced symptomatic relief following SABR. As such, patient-
reported quality of life should be explored in future prospective clinical trials. 
We also observed that 43% of patients had a transient small increase in tumour size on the 
first post-SABR scan followed by reduction on subsequent imaging. This is consistent with 
the literature about SABR for liver metastases [18] and stereotactic radiosurgery for brain 
metastases [19] showing transient increases in tumour size. 
A wide range of dose and fractionation schedules has been reported in the literature for 
SBRT of primary RCC, and it is unclear at this stage which schedule is optimal [8]. We chose 
the five-fraction schedule because it is one of the schedules that has been successfully 
employed in past publications [8], and because of our extensive institutional experience with 
using this schedule for the treatment of liver and central lung tumours [20]. 
Our study does have a number of limitations. Biopsies were not obtained in all of the 
patients. Some of these patients were referred for SABR because they were very frail and 
would not have been able to tolerate a biopsy. Even though the non-biopsied tumours were 
noted to have increased in size over time on serial imaging, it is possible that some of them 
were not malignant. The follow-up period is short at this stage, and as such, there may not 
have been enough time to document local failures or all potential late toxicities. RCC has 
been demonstrated to have slow growth in active surveillance studies [3], and McBride et 
al.’s study [17] demonstrated local failures after 30 months of follow-up. Furthermore, late 
toxicities such as declining renal function may continue to worsen over time. As such, with 
longer follow-up, we may find more cases of local failures and higher rates of late toxicities. 
Also, the small sample size limits our ability to draw conclusions from these results. Lastly, as 
with all retrospective studies, potentially not all toxicity data has been captured. We aim to 
address the above limitations by performing a prospective multicentre trial [21].  
In conclusion, SABR for primary RCC can be delivered safely, with minimal toxicity, and 
demonstrates excellent local control at early follow-up. This technique is extremely 
promising in the patient population with RCC that cannot tolerate surgery, and its use 
should be further evaluated in large prospective clinical trials. 
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Fig. 1. An example case of the dose distribution achieved for a patient treated using 
volumetric-modulated arc therapy. The isodose lines are shown with dose legend on the top 
right corner of the figure. 
  
Fig. 2. Change in size of the primary tumour after SABR over the follow-up period 
  
Fig. 3. An example case of serial CT scans of the abdomen (axial scans zoomed in on the left 
kidney tumour) before and after SABR for biopsy-proven RCC. The maximum tumour 
dimensions were: 4.5 cm 2 months before SABR (A), 4.9 cm 3 months after (B), 4.6 cm 6 
months after (C), 4.2 cm 9 months (D), 4.0 cm 12 months after (E), 3.2 cm 30 months after 
(F), 3.1 cm 35 months after (G), and 2.9 cm 42 months after SABR (H). 
Fig. 4. Change in estimated glomerular filtration rate after SABR. Dotted lines represent 
patients with baseline stage 4-5 chronic kidney disease 
  
 
Table 1. Planning dose constraints 
Organ at risk Constraint 
Renal cortices 
Volume receiving less than 
17.5 Gy >200 ml [9] 
Renal hilum (ipsilateral) V23Gy < 67% [9] 
Combined kidneys V16.8Gy < 67%* 
Spinal cord + 5mm Dmax <25.3 Gy [22] 
Stomach Dmax <32Gy [9] 
 
V18Gy <10cc [9] 
Duodenum Dmax <32Gy [9] 
 
V18Gy <5cc [9] 
Small bowel Dmax <35Gy [9] 
 
V19.5Gy <5cc [9] 
Large bowel Dmax <38Gy [9] 
 
V25 <20cc [9] 
Chest wall Dmax <105% [23] 




* in-house constraint 
  
Table 2. Patient baseline characteristics 
Median age (range) 73 (51-90) 
Median tumour size (range) 4.0 cm (1.0-14.6cm) 
Characteristic 
Number of patients 
(%) 
  Sex 
 Male 11 (69%) 
Female 5 (31%) 
  CKD stage 
 1 (eGFR >=90) 1 
2 (eGFR 60-89) 7 
3 (eGFR 30-59) 5 
4 (eGFR 15-29) 1 
5 (eGFR <15 or dialysis) 2 
  Histology 
 Clear cell 6 (38%) 
Papillary 2 (13%) 
Chromophobe 1 6%) 
Not biopsied or information not 
available 7 (44%) 
  T-category 
 T1 12 (75%) 
T2 0 (0%) 
T3 2 (13%) 
rT1 2 (13%) 
N-category 
 N0 14 (88%) 
N1 2 (13%) 
M-category 
 M0 10 (63%) 
M1 6 (38%) 
  Tumour laterality 
 Left 8 (50%) 
Right 8 (50%) 
  Prior treatment 
 Nephrectomy 2 (13%) 
Radiofrequency ablation 1 (6%) 
Tyrosine kinase inhibitor 1 (6%) 
Table 3. Dose/volume metrics for organs at risk 
Organ at risk Metric Mean (range) 
Renal cortices Volume receiving < 17.5Gy (ml) 238 (109-548) 
Renal hilum V23Gy (%) 37.0 (0-84.1) 
Combined kidney V16.8Gy (%) 24.1 (0-181.4) 
 
Mean dose (Gy) 7.6 (1.4-15.9) 
Ipsilateral kidney Mean dose (Gy) 16.3 (7.35-28.7) 
Contralateral kidney Mean dose (Gy) 3.3 (0.7-13.3) 
Spinal cord + 5mm Dmax (Gy) 12.2 (3.2-23.7) 
Small bowel Dmax (Gy) 23.3 (3.0-34.2) 
Large bowel Dmax (Gy) 26.7 (10.7-40) 
 
